Shares of Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) dropped 15.1% on Wednesday . The company traded as low as C$1.47 and last traded at C$1.57. Approximately 296,430 shares traded hands during mid-day trading, an increase of 264% from the average daily volume of 81,398 shares. The stock had previously closed at C$1.85.
Cardiol Therapeutics Price Performance
The company has a market cap of C$115.34 million, a P/E ratio of -2.73 and a beta of 0.70. The firm's 50-day moving average is C$1.87 and its two-hundred day moving average is C$1.70. The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
